

Erratum

Erratum to “CD26-processed RANTES(3–68), but not intact RANTES, has potent anti-HIV-1 activity” [Antiviral Res. 39 (1998) 175–187]¹

Dominique Schols ^{a,*}, Paul Proost ^b, Sofie Struyf ^b, Anja Wuyts ^b,
Ingrid De Meester ^c, Simon Scharpé ^c, Jo Van Damme ^b, Erik De Clercq ^a

^a *Laboratory of Experimental Chemotherapy, Rega Institute for Medical Research, Minderbroedersstraat 10,
B-3000 Leuven, Belgium*

^b *Laboratory of Molecular Immunology, Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium*

^c *Department of Clinical Biochemistry, University of Antwerp, B-2610 Wilrijk, Belgium*

Received 22 April 1998; accepted 14 July 1998

The Publisher regrets that Fig. 2 in the above paper was incorrectly printed. The correct figure as it should have appeared is published on the following page.

* Corresponding author. Tel.: +32-16-337357; fax: +32-16-337340; e-mail: dominique.schols@rega.kuleuven.ac.be.

¹ PII of original article S0166-3542(98)00039-4.




Fig. 2. Effects of RANTES and MIP-1 α on infection by the HIV-1 SF162 strain in PHA activated PBMC. Virus yields were monitored 10 days after infection by a p24 Ag ELISA on the cell supernatant. Results of a representative experiment out of three are shown. * Under the detection limit of the p24 Ag ELISA (< 5 pg/ml).